• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

SetPoint Medical Raises $140M to Support Commercialization of Rheumatoid Arthritis Therapy

by Fred Pennic 08/11/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– SetPoint Medical, a company focused on developing innovative therapies for chronic autoimmune diseases secures $140M in private financing. This includes the final $25M tranche of its Series C funding and a substantial $115M Series D round co-led by Elevage Medical Technologies and Ally Bridge Group. 

– The funding will fuel the commercialization of the SetPoint System, a groundbreaking neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis (RA), and advance the company’s pipeline for other autoimmune conditions.

Neuroimmune Modulation for Autoimmune Disease

The SetPoint System represents a first-of-its-kind approach to treating rheumatoid arthritis by utilizing neuroimmune modulation. This innovative therapy aims to modulate the body’s inflammatory response through targeted electrical stimulation of the vagus nerve. The successful commercialization of this technology could offer a significant new treatment option for individuals living with moderate-to-severe RA and holds promise for addressing other chronic autoimmune conditions in the future. The significant funding secured by SetPoint Medical underscores the potential of this novel therapeutic approach and its potential to transform the lives of millions affected by autoimmune diseases.

Preparing for Commercial Market Launch

SetPoint Medical is actively preparing for the commercial launch of its SetPoint System. To this end, the company has announced two key executive appointments. Erik Styacich, former Vice President of Sales at Valencia Technologies, has joined SetPoint as Vice President of Sales. Spencer Bailey, who brings extensive experience in market access and reimbursement from previous leadership roles at neuromodulation companies like MicroTransponder, Inc., has been appointed as Vice President of Market Access & Reimbursement.

“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the SetPoint System in select U.S. markets this year, with broader national expansion in 2026,” added Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical. “We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Corti Joins Coalition for Health AI to Advance Responsible and Safe AI in Healthcare

Joint Commission and CHAI Release First-Ever Guidance for Responsible AI in Healthcare

71% of Hospitals Now Use Predictive AI, But a Digital Divide Remains

71% of Hospitals Now Use Predictive AI, But a Digital Divide Remains

PHTI Report: Virtual OUD Solutions are Effective, But Don't Substantially Reduce Costs

PHTI Report: Virtual OUD Solutions are Effective, But Don’t Substantially Reduce Costs

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |